-
Eli Lilly (NYSE:LLY) has partnered with Hims & Hers Health and LifeMD to widen access to its GLP-1 obesity drugs in the US.
-
The agreements give eligible adults nationwide direct digital access to Zepbound and Foundayo through telehealth consultations and online prescribing.
-
Both collaborations exclude compounded versions of GLP-1 therapies and focus on prescription, pharmacy fulfillment and home delivery of branded products.
-
The new Hims & Hers and LifeMD channels for Zepbound and Foundayo matter, but investors should weigh Eli Lilly's wider risk picture too. We have also flagged 2 warning signs (1 major) for Eli Lilly.
Consider widening your watchlist to other healthcare names using 35 healthcare AI stocks .
Eli Lilly is a large US pharmaceuticals group with a US$1.2 trillion market cap that develops and markets human therapies across major regions including the United States, Europe, China and Japan. Extending access to GLP-1 obesity treatments fits directly into its broader prescription drug portfolio.
3 things going right for Eli Lilly that this headline doesn't cover.
Digital obesity deals push Eli Lilly deeper into consumer-style care
For Eli Lilly, plugging Zepbound and Foundayo into Hims & Hers and LifeMD reinforces a core Narrative catalyst that is already in play. The story is about turning strong GLP 1 demand into durable access through self pay and employer style channels, not just traditional insurance. These partnerships widen the funnel for obesity care and keep patients inside Lilly branded drugs rather than compounded alternatives, but they do not remove the existing pressure points around U.S. pricing trends, legal exposure on GLP 1 safety, or reliance on cardiometabolic volume to support the 2026 revenue guidance range of US$91b to US$92b.
See how these catalysts shape Eli Lilly's path to a $1,397 fair value .
The next telling checkpoint is how management talks about Zepbound and Foundayo volumes through digital and cash pay routes in the next earnings update for the quarter to 31 December 2026. Any fresh disclosure on self pay mix, net pricing or telehealth driven prescription share will show how much these Hims & Hers and LifeMD agreements are shaping the GLP 1 access story that analysts are using in their forecasts.
Add Eli Lilly to your Watchlist and get alerts as these catalysts play out.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LLY .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
